ReviewBMC medicine2022
New strategies to improve clinical outcomes for diabetic kidney disease.
Review in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Integrative multi-omics analysis identifies VCAN and ESM1 as candidate cell-type-associated biomarkers of NET-related glomerular injury in diabetic kidney disease.Renal failure · 2026Article
- Identification of diagnostic markers for diabetic kidney disease by weighted gene co‑expression network analysis and machine learning.International journal of molecular medicine · 2026Article
- Acylcarnitines and prediction of renal function decline in type 2 diabetes.BMJ open diabetes research & care · 2026Article
- The gut as a central hub for multi-organ crosstalk in aging.Cellular and molecular life sciences : CMLS · 2026Review
- Association of Cumulative Average Uric Acid to HDL Cholesterol Ratio with the Risk of Rapidly Declining Renal Function: A Retrospective Community-Based Cohort Study in Shanghai Undertaken on Elderly Subjects with Hypertension and Type 2 Diabetes Mellitus Patients.Risk management and healthcare policy · 2026Article
- Clustering-derived clinical subtypes and outcomes of chronic kidney disease in patients with diabetes: a multicenter cohort study.Frontiers in endocrinology · 2026Article
- Sodium-glucose cotransporter 2 inhibitors ameliorate glutathione cysteine ligase modifier-mediated oxidative stress and subsequent ferroptosis in proximal tubules of diabetic kidney disease.Redox report : communications in free radical research · 2025Article
- Global, regional, and national burden of chronic kidney disease among adolescents and emerging adults from 1990 to 2021.Renal failure · 2025Article
- Sulfur-Rich Garlic Extract (DNR) as a Promising Natural Therapeutic for Diabetic Nephropathy: Evidence from aInternational journal of molecular sciences · 2025Article
- Epidemiological trend in diabetic kidney disease (DKD) burden in China from 1990 to 2021, and projections for 2041: an analysis of the global burden of disease study 2021.BMC public health · 2025Article
- FTZ alleviates lipid deposition in diabetic kidney disease by AMPK/ACC/SREBP signaling pathway.Acta diabetologica · 2025Article
- Mechanisms of Xuefu Zhuyu decoction in treating diabetic kidney disease-induced renal fibrosis: UPLC-Q/TOF-MS, network pharmacology, and experimental validation.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025Article
- Modified Hu-Lu-Ba-Wan Alleviates Early-Stage Diabetic Kidney Disease via Inhibiting Interleukin-17A in Mice.Chinese journal of integrative medicine · 2025Article
- Mesenchymal Stem Cells Mediated Suppression of GREM2 Inhibits Renal Epithelial-Mesenchymal Transition and Attenuates the Progression of Diabetic Kidney Disease.International journal of stem cells · 2025Article
- Relationship between weekend catch-up sleep and the risk of diabetic kidney disease.Archives of endocrinology and metabolism · 2025Article
- Elucidating the Mechanism of Jisheng Shenqi Pills in the Treatment of Diabetic Kidney Disease: Network Pharmacology Combined with Experimental Verification.Endocrine, metabolic & immune disorders drug targets · 2025Article
- A review of advances in the treatment of diabetic nephropathy by modulating intestinal flora with natural products of traditional Chinese medicine.Frontiers in pharmacology · 2025Review
- Global burden of chronic kidney disease due to diabetes mellitus, 1990-2021, and projections to 2050.Frontiers in endocrinology · 2025Article
- A retrospective multi-site examination of chronic kidney disease using longitudinal laboratory results and metadata to identify clinical and financial risk.BMC nephrology · 2024Observational
- Curcumin targets CXCL16-mediated podocyte injury and lipid accumulation in diabetic kidney disease treatment.Archives of pharmacal research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetic kidney disease (DKD), the most common cause of kidney failure and end-stage kidney disease worldwide, will develop in almost half of all people with type 2 diabetes. With the incidence of type 2 diabetes continuing to increase, early detection and management of DKD is of great clinical importance. MAIN BODY: This review provides a comprehensive clinical update for DKD in people with type 2 diabetes, with a special focus on new treatment modalities. The traditional strategies for prevention and treatment of DKD, i.e., glycemic control and blood pressure management, have only modest effects on minimizing glomerular filtration rate decline or progression to end-stage kidney disease. While cardiovascular outcome trials of SGLT-2i show a positive effect of SGLT-2i on several kidney disease-related endpoints, the effect of GLP-1 RA on kidney-disease endpoints other than reduced albuminuria remain to be established. Non-steroidal mineralocorticoid receptor antagonists also evoke cardiovascular and kidney protective effects.
conclusionWith these new agents and the promise of additional agents under clinical development, clinicians will be more able to personalize treatment of DKD in patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.